摘要
目的探讨乳酸脱氢酶A的α复合体4-L2(NDUFA4L2)在胶质瘤中的表达情况及临床意义。方法利用癌症基因组图谱(TCGA)、中国胶质瘤基因组图谱(CGGA)数据库分析NDUFA4L2在胶质瘤中的mRNA表达情况,分析其与患者临床病理分级和预后的关系。进一步收集不同级别的胶质瘤组织标本行免疫组化检测,验证NDUFA4L2在不同级别胶质瘤中蛋白表达的差异。收集62例胶质瘤患者的组织标本和随访资料,采用RT-PCR法检测NDUFA4L2在胶质瘤中的表达并分析其与预后的关系。结果通过分析TCGA、CGGA数据库,发现胶质瘤组织中NDUFA4L2的表达随着肿瘤分级的增高而增高(P<0.05),高表达NDUFA4L2预示着患者生存期较短。在临床标本验证中的结果与上述生物信息学分析相一致。结论NDUFA4L2在胶质瘤组织中的表达与病理分期和预后有关,可能是胶质瘤的一个潜在肿瘤标志物。
Objective To investigate the expression of NADH dehydrogenase(ubiquinone)1 alpha subcomplex 4-like 2(NDUFA4L2)in gliomas and its clinical significance.Methods The Cancer Genome Atlas(TCGA)and Chinese Glioma Genome Atlas(CGGA)databases were used to analyze the mRNA expression of NDUFA4L2 in glioma and its relationship with the clinical pathological grade and prognosis of the patients.The glioma tissue specimens of different grades were further collected for immunohistochemical detection to verify the difference of protein expression of NDUFA4L2 in different grades of gliomas.The tussue specimens and follow-up data of 62 patients with glioma were collected.Real-time quantitative polymerase chain reaction(RT-PCR)method was used to detect the expression of NDUFA4L2 in glioma and its relationship with prognosis was analyzed.Results By analyzing the TCGA and CGGA databases,it was found that the expression of NDUFA4L2 in glioma tissues increased with the increase of the tumor grade(P<0.05).High expression of NDUFA4L2 indicated a shorter survival period for the patients.The results in the clinical specimen verification were consistent with the above-mentioned bioinformatic analysis.Conclusion The expression of NDUFA4L2 in glioma tissues is related to the pathological stage and prognosis,and NDUFA4L2 may be a potential tumor marker of glioma.
作者
李春芽
陈远兵
梁银华
唐淼
曹武阳
LI Chun-ya;CHEN Yuan-bing;LIANG Yin-hua(Teaching and Research Section of Clinical Nursing, Xiangya Hospital of Central South University, Changsha 410008, China)
出处
《中国临床新医学》
2021年第11期1127-1130,共4页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
关键词
胶质瘤
乳酸脱氢酶A的α复合体4-L2
预后
Glioma
NADH dehydrogenase(ubiquinone)1 alpha subcomplex 4-like 2(NDUFA4L2)
Prognosis